Related Experiment Videos
Flow cytometric analysis of CD 62P expression in patients with acute myocardial infarction
V Dymicka-Piekarska1, H Kemona, M Mantur
1Department of Clinical Laboratory Diagnostics, Institute of Laboratory Diagnostics, Medical Academy of Białystok.
Insights
Platelet activation marker CD 62P (P-selectin) expression differs in acute myocardial infarction patients based on treatment. Thrombolytic therapy, like streptokinase, significantly inhibits platelet activation compared to heparin and aspirin alone.
Area of Science:
- Cardiology
- Hematology
- Biochemistry
Background:
- Platelets play a crucial role in heart disease pathogenesis, including myocardial infarction.
- Platelet activation involves structural changes and the release of molecules like CD 62P (P-selectin).
Purpose of the Study:
- To evaluate CD 62P expression in acute myocardial infarction patients.
- To assess the influence of disease duration and treatment type on CD 62P levels.
Main Methods:
- Studied 29 patients with acute myocardial infarction, divided into two treatment groups: heparin/aspirin and streptokinase/heparin/aspirin.
- Included a control group of 21 healthy subjects.
- Measured CD 62P expression before and after thrombin activation.
Main Results:
- CD 62P expression was influenced by infarction duration and treatment.
- Thrombolytic therapy (streptokinase) significantly inhibited platelet activation.
- Patients receiving streptokinase showed lower CD 62P expression than those on heparin and aspirin.
Conclusions:
- Thrombolytic therapy effectively inhibits platelet activation in acute myocardial infarction.
- Treatment with streptokinase demonstrates a greater inhibitory effect on platelet activation compared to heparin and aspirin alone.
Abstract:
Much attention has been paid to the role of platelets in the pathogenesis of heart diseases, e.g. ischaemic disease and myocardial infarction. During platelet activation changes appear both in the internal structure and in the membrane. The release reaction is associated with the appearance of CD 62P (P-selectin). The aim of the present study was evaluate CD 62P expression in patients with acute myocardial infarction according to the disease duration and the type of treatment. We study 29 patients with acute myocardial infarction (MI). The patients were divided into two groups: group A--15 patients treated with heparin and aspirin and group B--14 patients treated with streptokinase, heparin and aspirin. The control group consisted of 21 healthy subjects. We indicated that P-selectin expression is influenced by infarction duration and type of treatment. Our study demonstrates that thrombolytic therapy inhibits platelet activation. Patients receiving streptokinase showed lower CD 62P expression than those treated only with heparin and aspirin, both before and after platelet activation with thrombin.